Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard?

Antonio Galvano, Francesco Passiglia, Antonio Russo, Giuseppe Bronte, Antonio Russo, Antonio Galvano, Francesco Passiglia, Giuseppe Bronte

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)


Tumor angiogenesis is one of the main pathways targeted to treat cancer. Bevacizumab added survival benefit when combined with platinum-based chemotherapy in NSCLC. Recently, Phase III trials showed survival benefit when anti-angiogenic drugs are added to docetaxel as second-line treatment for NSCLC. These anti-angiogenic agents include nintedanib and ramucirumab, a tyrosine-kinase inhibitor and a monoclonal antibody, respectively, which target receptors involved in angiogenesis. These studies have some similarities and differences. We propose a new algorithm for treatment sequences in performance status 0-1 patients with non-oncogene-addicted NSCLC type adenocarcinoma. Indeed clearer scientific evidences are available for this subgroup of patients.
Original languageEnglish
Pages (from-to)1-5
Number of pages5
JournalExpert Opinion on Biological Therapy
Publication statusPublished - 2016

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry


Dive into the research topics of 'Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard?'. Together they form a unique fingerprint.

Cite this